DVT is an increasing condition that affects as many as 900,000 people(1 to 2 per 1,000)each year in the United States.
Estimates suggest that 60,000-100,000 Americans die of DVT/PE each year.
Sudden death is the first symptom in about 25% of people who have a PE. Among people who have had a DVT,one-half will have long-term complications(post-thrombotic syndrome) such as swelling,pain,discoloration,and scaling in the affected limb.
One-third(about 33%) of people with DVT/PE will have a recurrence within 10 years. Approximately 5 to 8% of the U.S. population has one of several genetic risk factors,also known as inherited thrombophilias in which a genetic defect can be identified that increases the risk for thrombosis.(according to https://www.cdc.gov/ncbddd/dvt/data.html)
Many factors determine your risk for DVT but studies show you're at highest risk five to ten days after surgery.
With today's shorter hospital stay. that's most likely when you're recovering at home,away from the watchful eye of your health care providers. Therefore,it's vital that life-saving DVT prevention doesn't end at the time of discharge after surgery- but continues at home throughout your most vulnerable days. Your physician can prescribe DVT prevention that you can use at home,including both mechanical and pharmacological prophylaxis.
Fact is,nearly 50 percent of all DVT cases happen after a patient is discharged. Triple Play VT® reduces this risk to patients- and their providers- by decreasing the likelihood of life-threatening,post-surgical DVT during the VULNERABLE first week after discharge. Designed to promote the continuum of care from the hospital to home after surgery, CLYCLI18 is compact,portable and easy for patients to use, The result is greater compliance,positive patient experiences and better outcomes.
They not only harm patients,but hospitals as well,resulting in costly ﬁnes or loss of reimbursement. The Centers
for Medicare & Medicaid Services have deemed DVT a never event. Still,DVT is the leading cause of preventable hospital deaths.
Research shows one in 100 patients admitted to a hospital dies because of pulmonary embolism (PE),
which is a result of DVT. Hospitals and surgical centers can affordably prevent life-threatening DVT never events with Circul8 take home DVT,
using DVT prophylaxis will reduce the incidence of DVT never events during the post-operative period by two-thirds and will prevent death
from PE in one patient out of every 200 major operations.
The cost to diagnose and treat DVT and its effects in the Unites States is estimated to be as much as $23.8 billion per year. According to the Centers for Medicare & Medicaid Services (CMS), DVT treatment costs an average of $50,937 per patient.
We welcome you to see who we are and what we reprsent. Watch our video below!
Fill out this form or call us directly at 800.993.8244